Breaking News

Soligenix Licenses BTG’s CoVaccine HT for SARS-CoV-2

Novel adjuvant has been shown to enhance both cell-mediated and antibody-mediated immunity

By: Contract Pharma

Contract Pharma Staff

Soligenix, Inc., a biopharma company focused on developing products to treat rare diseases, has entered an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp. for SARS-CoV-2, the cause of COVID-19 and pandemic flu. Terms were not disclosed. CoVaccine HT is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity. Soligenix and its collaborat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters